BCM
SGTX

Bridgeway Capital Management’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

Bridgeway Capital Management’s Portfolio SGTX Stock Details SGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-9,615
Closed -$216K – 1473
2023
Q2 		$216K Hold
9,615
– – 0.01% 1121
2023
Q1 		$116K Hold
9,615
– – ﹤0.01% 1207
2022
Q4 		$43.8K Sell
9,615
-1,923
-17% -$11K ﹤0.01% 1308
2022
Q3 		$76K Hold
11,538
– – ﹤0.01% 1317
2022
Q2 		$125K Sell
11,538
-3,847
-25% -$51.7K ﹤0.01% 1188
2022
Q1 		$294K Hold
15,385
– – 0.01% 1088
2021
Q4 		$552K Buy
+15,385
New +$876K 0.01% 954

Other funds holding SGTX

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Bridgeway Capital Management's SGTX Position: Q3 2023 in Review

Bridgeway Capital Management sold out of Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q3 2023, closing a stake of 9,615 shares — an estimated $216K sold.

Bridgeway Capital Management first reported a position in SGTX in Q4 2021 and held it in 7 quarters. The position peaked at $552K in Q4 2021. 1 fund tracked by Wall St. Rank holds SGTX as of Q3 2023.

  • Bridgeway Capital Management reported no remaining Sigilon Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Bridgeway Capital Management sold 9,615 Sigilon Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $216K.
  • Bridgeway Capital Management first reported a position in Sigilon Therapeutics, Inc. Common Stock in Q4 2021 and held it in 7 quarters.
  • Bridgeway Capital Management's Sigilon Therapeutics, Inc. Common Stock position peaked at $552K in Q4 2021.
  • 1 fund tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Bridgeway Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.